Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Young KH, et al. Among authors: kahl bs. Blood. 2008 Oct 15;112(8):3088-98. doi: 10.1182/blood-2008-01-129783. Epub 2008 Jun 17. Blood. 2008. PMID: 18559976 Free PMC article.
Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma.
Fenske TS, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, McCoy AG, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Fenske TS, et al. Among authors: kahl bs. Leuk Lymphoma. 2005 Oct;46(10):1441-8. doi: 10.1080/10428190500144656. Leuk Lymphoma. 2005. PMID: 16194889
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network. Kahl BS, et al. Ann Oncol. 2006 Sep;17(9):1418-23. doi: 10.1093/annonc/mdl127. Epub 2006 Jun 9. Ann Oncol. 2006. PMID: 16766582 Free article. Clinical Trial.
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Robertson MJ, et al. Among authors: kahl bs. J Clin Oncol. 2007 May 1;25(13):1741-6. doi: 10.1200/JCO.2006.09.3146. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389337 Clinical Trial.
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.
Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S. Leshchenko VV, et al. Among authors: kahl bs. Blood. 2010 Aug 19;116(7):1025-34. doi: 10.1182/blood-2009-12-257485. Epub 2010 Apr 28. Blood. 2010. PMID: 20427703 Free PMC article.
284 results